G G Zhanel

Summary

Affiliation: University of Manitoba
Country: Canada

Publications

  1. doi request reprint Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    Drugs 74:31-51. 2014
  2. doi request reprint Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study
    George G Zhanel
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0J9
    J Antimicrob Chemother 68:i7-22. 2013
  3. doi request reprint Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada
    Drugs 73:159-77. 2013
  4. doi request reprint Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, MS673 Health Sciences Centre, 820 Sherbrook Street, Winnipeg R3A 1R9, Canada
    J Antimicrob Chemother 67:1706-11. 2012
  5. doi request reprint Oritavancin: mechanism of action
    George G Zhanel
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    Clin Infect Dis 54:S214-9. 2012
  6. ncbi request reprint Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, and Department of Medicine, Health Sciences Centre, Winnipeg, Man, Canada
    Int J Antimicrob Agents 27:468-75. 2006
  7. pmc Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa
    George G Zhanel
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 50:2228-30. 2006
  8. ncbi request reprint Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    Int J Antimicrob Agents 28:465-71. 2006
  9. ncbi request reprint Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 820 Sherbrook Street, Winnipeg, R3A 1R9, Canada
    J Antimicrob Chemother 59:144-7. 2007
  10. ncbi request reprint Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba 5th floor, Basic Medical Sciences Building, Winnipeg, Canada R3E 0W3
    J Antimicrob Chemother 58:112-6. 2006

Collaborators

Detail Information

Publications112 found, 100 shown here

  1. doi request reprint Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    Drugs 74:31-51. 2014
    ..aeruginosa infections with this agent. Currently, ceftolozane/tazobactam is being evaluated in three phase III trials for the treatment of cUTI, cIAI, and VABP. ..
  2. doi request reprint Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study
    George G Zhanel
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0J9
    J Antimicrob Chemother 68:i7-22. 2013
    ..The purpose of the CANWARD study was to assess the antimicrobial activity of a variety of available agents against 22,746 pathogens isolated from patients in Canadian hospitals between 2007 and 2011...
  3. doi request reprint Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada
    Drugs 73:159-77. 2013
    ..Finally, the increased activity of ceftazidime-avibactam versus P. aeruginosa may be of clinical benefit in patients with suspected or documented P. aeruginosa infections...
  4. doi request reprint Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, MS673 Health Sciences Centre, 820 Sherbrook Street, Winnipeg R3A 1R9, Canada
    J Antimicrob Chemother 67:1706-11. 2012
    ..This study assessed the pharmacodynamics of ceftaroline against penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model...
  5. doi request reprint Oritavancin: mechanism of action
    George G Zhanel
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    Clin Infect Dis 54:S214-9. 2012
    ....
  6. ncbi request reprint Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, and Department of Medicine, Health Sciences Centre, Winnipeg, Man, Canada
    Int J Antimicrob Agents 27:468-75. 2006
    ..This study reports higher rates of antibiotic resistance in US versus Canadian outpatient urinary isolates of E. coli and demonstrates the continuing evolution of resistance to antimicrobial agents...
  7. pmc Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa
    George G Zhanel
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 50:2228-30. 2006
    ..Antibiotic combinations using levofloxacin with any antibiotic with individual activity against P. aeruginosa resulted in synergistic lowering (an at-least-fourfold reduction) of the isolate's MPC...
  8. ncbi request reprint Molecular characterisation of Canadian paediatric multidrug-resistant Streptococcus pneumoniae from 1998-2004
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    Int J Antimicrob Agents 28:465-71. 2006
    ..In conclusion, paediatric MDR S. pneumoniae simultaneously resistant to penicillin, erythromycin and T/S are genetically similar and disseminating across Canada. Prevnar provides excellent coverage of paediatric MDR S. pneumoniae...
  9. ncbi request reprint Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 820 Sherbrook Street, Winnipeg, R3A 1R9, Canada
    J Antimicrob Chemother 59:144-7. 2007
    ..12 mg/L) Streptococcus pneumoniae. This study assessed the pharmacodynamic activity of ertapenem against penicillin-susceptible and penicillin-non-susceptible S. pneumoniae using an in vitro pharmacodynamic model...
  10. ncbi request reprint Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba 5th floor, Basic Medical Sciences Building, Winnipeg, Canada R3E 0W3
    J Antimicrob Chemother 58:112-6. 2006
    ..This study assessed garenoxacin fAUC24/MIC against ciprofloxacin-resistant Streptococcus pneumoniae using an in vitro pharmacodynamic model...
  11. doi request reprint Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Diagn Microbiol Infect Dis 62:67-80. 2008
    ..aeruginosa), respectively...
  12. ncbi request reprint Tigecycline: a novel glycylcycline antibiotic
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba, Canada
    Expert Rev Anti Infect Ther 4:9-25. 2006
    ..e., nausea, vomiting and diarrhea) the most commonly reported. Tigecycline is a promising new broad-spectrum parenteral monotherapy for the treatment of patients with Gram-positive and -negative bacterial infections...
  13. ncbi request reprint Antibiotic resistance in outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Int J Antimicrob Agents 26:380-8. 2005
    ..This study reports higher rates of antibiotic resistance in US versus Canadian outpatient urinary isolates and demonstrates the continuing evolution of resistance to antimicrobial agents...
  14. pmc Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs vary
    George G Zhanel
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 49:1943-8. 2005
    ..In conclusion, free-telithromycin concentrations in serum and ELF simulating C(max)/MIC > or = 3.5 and AUC(0-24 h)/MIC > or = 25 completely eradicated (> or =4 log(10) killing) macrolide-resistant S. pneumoniae at 24 and 48 h...
  15. ncbi request reprint Ertapenem: review of a new carbapenem
    George G Zhanel
    Health Sciences Center, Clinical Microbiology, MS673 820, Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada
    Expert Rev Anti Infect Ther 3:23-39. 2005
    ..Ertapenem is a promising new carbapenem with excellent efficacy and safety for the treatment of a variety of community-acquired infections. It also appears to be of great value as an outpatient parenteral antimicrobial therapy...
  16. ncbi request reprint Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    Int J Antimicrob Agents 24:529-35. 2004
    ..In the meantime, appropriate antibiotic selection and optimal dosing strategies should aim to eradicate the causative pathogen before a resistant efflux mutant can emerge...
  17. ncbi request reprint Pharmacodynamic activity of telithromycin against macrolide-susceptible and macrolide-resistant Streptococcus pneumoniae simulating clinically achievable free serum and epithelial lining fluid concentrations
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
    J Antimicrob Chemother 54:1072-7. 2004
    ..pneumoniae simulating clinically achievable free serum and epithelial lining fluid (ELF) concentrations...
  18. ncbi request reprint Comparative review of the carbapenems
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 67:1027-52. 2007
    ..aeruginosa than meropenem. Clinical trials are required to establish the efficacy and safety of doripenem in moderate to severe infections, including nosocomial infections...
  19. doi request reprint Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum beta-lactamase-producing Escherichia coli using an in vitro model
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, MS673 Microbiology, 820 Sherbrook Street, Winnipeg, Canada R3A 1R9
    J Antimicrob Chemother 61:643-6. 2008
    ..This study assessed the pharmacodynamic activity of ertapenem against multidrug-resistant (MDR) genotypically characterized extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli using an in vitro model...
  20. doi request reprint Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    J Antimicrob Chemother 66:1301-5. 2011
    ..aureus (hVISA), VISA and vancomycin-resistant S. aureus (VRSA) using an in vitro model...
  21. doi request reprint Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study
    George G Zhanel
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0J9
    Diagn Microbiol Infect Dis 69:291-306. 2011
    ....
  22. pmc Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008)
    George G Zhanel
    Clinical Microbiology, Health Sciences Centre, 820 Sherbrook St, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 54:4684-93. 2010
    ..The prevalence of MRSA was 27.0% (of which genotypically 27.6% were CA-MRSA), while ESBL-producing E. coli occurred in 4.9% of isolates. An MDR phenotype was common in P. aeruginosa...
  23. doi request reprint New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 70:859-86. 2010
    ....
  24. doi request reprint Overview of seizure-inducing potential of doripenem
    George G Zhanel
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drug Saf 32:709-16. 2009
    ..The seizure potential of doripenem should be evaluated further in patients at increased risk for seizure...
  25. doi request reprint Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems us
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Antimicrob Chemother 64:824-8. 2009
    ..This study assessed the in vitro pharmacodynamic activity of tigecycline against E. coli with ESBLs, AmpCs and CRS...
  26. doi request reprint Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Antimicrob Chemother 64:364-9. 2009
    ..This study compared the pharmacodynamics of ceftobiprole and vancomycin against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) using an in vitro model...
  27. doi request reprint Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 69:809-31. 2009
    ..Further clinical studies are needed to determine the efficacy and safety of ceftaroline, and to define its role in patient care...
  28. pmc In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae
    George G Zhanel
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 53:1690-2. 2009
    ..The potential clinical utility of iclaprim to treat patients with pneumococcal infections may depend upon the current prevalence of resistance to trimethoprim-sulfamethoxazole in this pathogen...
  29. ncbi request reprint Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Am J Clin Dermatol 9:245-54. 2008
    ..Further clinical studies are needed to determine the efficacy and safety of ceftobiprole and to define its role in patient care...
  30. pmc Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 52:1430-7. 2008
    ..aeruginosa, H. influenzae, Enterococcus spp., S. pneumoniae, and K. pneumoniae are the most common isolates recovered from clinical specimens in Canadian ICUs. A MDR phenotype is common for P. aeruginosa isolates in Canadian ICUs...
  31. doi request reprint Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections
    George G Zhanel
    MS 673 Microbiology, Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada
    Expert Rev Anti Infect Ther 6:67-81. 2008
    ..Both telavancin and dalbavancin show promise as alternative treatments for patients with serious infections caused by resistant Gram-positive pathogens...
  32. ncbi request reprint Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae
    George G Zhanel
    MS 673 Microbiology, Department of Clinical Microbiology, Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada
    Expert Opin Emerg Drugs 8:297-321. 2003
    ..Clinical trials focusing on respiratory infections indicate bacteriological and clinical cure rates similar to comparators, even in patients infected with macrolide-resistant strains...
  33. pmc In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
    G G Zhanel
    Department of Medical Microbiology and Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 41:863-5. 1997
    ..12 microg/ml) (n = 10), and was inactive against C. neoformans (MIC90, >10.24 microg/ml) (n = 15) and B. dermatitidis (MIC90, 16 microg/ml) (n = 29)...
  34. ncbi request reprint A critical review of the fluoroquinolones: focus on respiratory infections
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 62:13-59. 2002
    ..Prudent use of the new fluoroquinolones will be required to minimise the development of resistance to these agents...
  35. ncbi request reprint Mecillinam activity compared to ampicillin, trimethoprim/sulfamethoxazole, ciprofloxacin and nitrofurantoin against urinary tract isolates of gram-negative bacilli
    G G Zhanel
    Department of Medical Microbiology, Faculties of Medicine, University of Manitoba, Winnipeg, Man, Canada
    Chemotherapy 44:391-6. 1998
    ..9% of ampicillin-resistant E. coli and 95.9% of trimethoprim/sulfamethoxazole-resistant E. coli. We conclude that mecillinam should be reevaluated for potential use in the treatment of community-acquired urinary tract infections...
  36. pmc A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group
    G G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Health Sciences Centre, Manitoba, Canada
    Antimicrob Agents Chemother 44:1089-92. 2000
    ..0, 18.9, 7.4, 0.1, and 1.2%, respectively. The majority of E. coli isolates resistant to ampicillin, trimethoprim-sulfamethoxazole, or ciprofloxacin were susceptible (MIC, <16 microg/ml) to mecillinam...
  37. pmc Nitrofurantoin is active against vancomycin-resistant enterococci
    G G Zhanel
    Departments of Clinical Microbiology and Medicine, Health Sciences Centre and Faculties of Medicine and Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 45:324-6. 2001
    ..gallinarum isolates. We conclude that nitrofurantoin may provide effective treatment of urinary tract infections caused by vancomycin-resistant enterococci...
  38. ncbi request reprint In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae
    G G Zhanel
    Department of Medical Microbiology, Faculties of Medicine and Pharmacy, University of Manitoba, Canada
    J Antimicrob Chemother 47:435-40. 2001
    ..pneumoniae below the level of detection without regrowth or development of resistance over 48 h. This study also demonstrated the poor activity of ciprofloxacin against S. pneumoniae...
  39. ncbi request reprint Review of macrolides and ketolides: focus on respiratory tract infections
    G G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    Drugs 61:443-98. 2001
    ..Few pharmacoeconomic studies involving macrolides are presently available. The ketolides are being developed in an attempt to address the increasingly prevalent problems of macrolide-resistant and multiresistant organisms...
  40. ncbi request reprint The ketolides: a critical review
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 62:1771-804. 2002
    ..The addition of the ketolides in the era of antibacterial resistance provides clinicians with more options in the treatment of respiratory infections...
  41. pmc Influence of human serum on antifungal pharmacodynamics with Candida albicans
    G G Zhanel
    Faculty of Medicine, Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 45:2018-22. 2001
    ..Generally speaking, antifungal agents with high protein binding exhibited some form of reduced activity (MIC, killing, or PAFE) in the presence of serum compared to those with low protein binding...
  42. ncbi request reprint Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections
    G G Zhanel
    University of Manitoba, Health Sciences Centre, Winnipeg, Canada
    Curr Opin Pharmacol 1:459-63. 2001
    ....
  43. ncbi request reprint Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    J Antimicrob Chemother 49:807-12. 2002
    ..When simulated free AUC(0-24)/ MIC was <16, gemifloxacin allowed regrowth of high-level ciprofloxacin-resistant strains...
  44. ncbi request reprint Ketolides in the treatment of respiratory infections
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
    Expert Opin Pharmacother 3:277-97. 2002
    ..Ketolides have similar safety profiles to the newer macrolides. In summary, early clinical trials support the clinical efficacy of the ketolides in common RTIs, including activity against macrolide-resistant pathogens...
  45. ncbi request reprint Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Diagn Microbiol Infect Dis 45:63-7. 2003
    ..Efflux alone conferred low level ciprofloxacin resistance in 3 isolates. Significant reserpine-sensitive efflux of the new fluoroquinolones was not observed...
  46. pmc Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents
    G G Zhanel
    Department of Medical Microbiology, University of Manitoba, Canada
    Antimicrob Agents Chemother 42:2446-8. 1998
    ..6%) and Candida glabrata (35.7%). Susceptibilities to all antifungal agents tested, including LY303366, were similar to those reported previously for Candida species isolated from blood...
  47. ncbi request reprint Antibiotic activity against urinary tract infection (UTI) isolates of vancomycin-resistant enterococci (VRE): results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study (NAVRESS)
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada R3A 1R9
    J Antimicrob Chemother 52:382-8. 2003
    ..The purpose of this study was to assess the prevalence of vancomycin-resistant enterococci (VRE) in urinary isolates in North America, and the activity of various antibiotics against VRE...
  48. pmc Comparison of CO2 generation (BACTEC) and viable-count methods to determine the postantibiotic effect of antimycobacterial agents against Mycobacterium avium complex
    G G Zhanel
    Department of Medical Microbiology and Faculty of Pharmacy, University of Manitoba, Health Sciences Centre, Winnipeg, Canada
    Antimicrob Agents Chemother 42:184-7. 1998
    ..3 h), rifampin (9.7 h), and rifabutin (9.5 h), while the shortest PAEs resulted from clofazimine (1.7 h) and ethambutol (1.1 h) exposure. CO2 generation is a valid and efficient means of determining in vitro PAEs against MAC...
  49. pmc Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus
    G G Zhanel
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 42:2427-30. 1998
    ..Albumin was demonstrated to be almost solely responsible for changes in the aforementioned pharmacodynamic parameters of LY333328...
  50. ncbi request reprint Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, and Health Sciences Centre, MS673 820 Sherbrook Street, Winnipeg, Manitoba, Canada R3A 1R9
    J Antimicrob Chemother 52:83-8. 2003
    ..pneumoniae simulating clinically achievable free serum (S), epithelial lining fluid (ELF) and middle ear fluid (MEF) concentrations...
  51. ncbi request reprint Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model
    S A Zelenitsky
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada
    Chemotherapy 44:1-6. 1998
    ..Ciprofloxacin-containing regimens demonstrated the most bacterial kill with subsequent doses, however, bacterial counts at 24 h were similar to those of other combination regimens...
  52. pmc Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides
    D J Hoban
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Health Sciences Centre, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 45:2147-50. 2001
    ..06 and 0.03 microg/ml, respectively) and erm(B) (MIC(90), 0.06 and 0.03 microg/ml, respectively) strains of S. pneumoniae...
  53. doi request reprint Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007
    M McCracken
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    J Antimicrob Chemother 64:552-5. 2009
    ..baumannii cases identified through the Canadian Ward Surveillance Study (CANWARD). In addition, clinical cases involving MDR carbapenem-resistant A. baumannii are also detailed in this report...
  54. ncbi request reprint Macrolide resistance mechanisms among Streptococcus pneumoniae isolated over 6 years of Canadian Respiratory Organism Susceptibility Study (CROSS) (1998 2004)
    A K Wierzbowski
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Antimicrob Chemother 60:733-40. 2007
    ..Furthermore, the genetic relatedness, serotype distribution and antibiotic susceptibility profile among S. pneumoniae isolates with dual erythromycin ribosomal methylase [Erm(B)] and efflux pump [Mef(A)] were analysed...
  55. pmc Screening of stool samples for identification of vancomycin-resistant Enterococcus isolates should include the methyl-alpha-D-glucopyranoside test to differentiate nonmotile Enterococcus gallinarum from E. faecium
    C Y Turenne
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    J Clin Microbiol 36:2333-5. 1998
    ..faecium, whereas MDG identified 11 of the 33 isolates as nonmotile E. gallinarum. The MDG results were confirmed by sequencing the 16S rDNA V6-to-V8 region. We conclude that the MDG test is a necessary component of routine VRE screening...
  56. pmc Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model
    S A Zelenitsky
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 43:592-7. 1999
    ..No significant differences between the pharmacodynamics of LY-gentamicin combination regimens containing Gq24 h versus those containing Gq8h were detected...
  57. pmc Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 47:1867-74. 2003
    ..Despite decreases in the rates of antibiotic consumption in Canada over the 5-year period, the rates of both high-level penicillin-resistant and multidrug-resistant S. pneumoniae isolates are increasing in Canada...
  58. pmc Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 50:2251-4. 2006
    ..0%) or nitrofurantoin (4.0%) was less common. Only 10.8% of isolates were resistant to ciprofloxacin alone. Fluoroquinolone-resistant isolates of E. coli from urine were frequently multidrug resistant...
  59. pmc Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 47:1875-81. 2003
    ..In summary, the incidence of beta-lactamase-positive H. influenzae strains in Canada is decreasing (18.6% in 2001-2002), while the incidence of beta-lactamase-positive M. catarrhalis strains has remained constant (90.0% in 2001-2002)...
  60. pmc Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics
    H J Smith
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
    Antimicrob Agents Chemother 48:3630-5. 2004
    ....
  61. ncbi request reprint Comparative in vitro activity of PGE 9262932 and fluoroquinolones against Canadian clinical Streptococcus pneumoniae isolates, including molecularly characterized ciprofloxacin-resistant isolates
    Heather J Adam
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba 730 William Avenue, Winnipeg, Manitoba, R3E 0W3, Canada
    J Antimicrob Chemother 58:202-4. 2006
    ....
  62. doi request reprint Characterization of plasmids encoding CMY-2 AmpC beta-lactamases from Escherichia coli in Canadian intensive care units
    Patricia J Baudry
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada R3A 1R9
    Diagn Microbiol Infect Dis 65:379-83. 2009
    ....
  63. ncbi request reprint Evolving patterns of resistance to respiratory pathogens in Canada
    D J Hoban
    Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, Manitoba
    Can Respir J 6:27A-30A. 1999
    ..To date, there have been only a few reports of resistance to the fluoroquinolones. The apparent increase in the rate of development of resistance and cross-resistance will lead to new therapeutic challenges...
  64. pmc In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients
    D J Hoban
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 43:1463-4. 1999
    ..Fluconazole resistance (MIC >/= 64 microg/ml) was not identified in any of the C. albicans (n = 513), Candida parapsilosis (n = 78), Candida tropicalis (n = 62), or C. neoformans (n = 38) isolates tested...
  65. pmc In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study)
    A Walkty
    Health Sciences Centre, Department of Clinical Microbiology, MS673B 820 Sherbrook St, Winnipeg, Manitoba R3A1R9, Canada
    Antimicrob Agents Chemother 55:2992-4. 2011
    ..These data suggest that the ceftazidime-NXL104 combination may prove useful for treating many P. aeruginosa infections...
  66. pmc In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008
    A Walkty
    Health Sciences Centre, Department of Medicine, Winnipeg, Manitoba, Canada R3A 1R9
    Antimicrob Agents Chemother 53:4924-6. 2009
    ..All multidrug-resistant (n = 76) P. aeruginosa isolates were susceptible to colistin (MIC, < or = 2 microg/ml). These data support a role for colistin in the treatment of infections caused by multidrug-resistant P. aeruginosa...
  67. pmc Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants
    Heather J Smith-Adam
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, R3A 1R9 Canada
    Antimicrob Agents Chemother 49:846-8. 2005
    ..Fluoroquinolone resistance mechanisms, whether efflux or chromosomally mediated, remained stable in both clinical and laboratory-derived mutants...
  68. doi request reprint Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America
    Patricia J Baudry
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Canada
    Diagn Microbiol Infect Dis 63:319-26. 2009
    ..We report the 1st qepA-producing E. coli in North America...
  69. pmc Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides
    Aleksandra K Wierzbowski
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 49:4635-40. 2005
    ..In conclusion, increased expression of mef(E) is associated with higher levels of macrolide resistance in macrolide-resistant S. pneumoniae...
  70. ncbi request reprint Clinical implications of macrolide resistance in community-acquired respiratory tract infections
    Daryl J Hoban
    Health Science Centre, Department of Medical Microbiology, MS673 Thorlakson Building, 820, Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada
    Expert Rev Anti Infect Ther 4:973-80. 2006
    ..These findings suggest that susceptibility data may underestimate clinical utility and that clarithromycin still has a place in the empiric treatment of respiratory infections...
  71. pmc Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005
    Heather J Adam
    Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 51:198-207. 2007
    ..Continued surveillance and molecular analysis of fluoroquinolone-resistant S. pneumoniae in Canada are essential for appropriate empirical treatment of infections and early detection of novel resistance mechanisms...
  72. pmc Characterization of cefoxitin-resistant Escherichia coli isolates from recreational beaches and private drinking water in Canada between 2004 and 2006
    L F Mataseje
    National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 53:3126-30. 2009
    ..CMY-2-producing plasmids predominantly belonged to replicon groups I1-Igamma, A/C, and K/B. The majority of the E. coli isolates belonged to the nonvirulent phylogenetic groups A and B1...
  73. ncbi request reprint Presence of ROB-1 beta-lactamase correlates with cefaclor resistance among recent isolates of Haemophilus influenzae
    J A Karlowsky
    Department of Medical Microbiology and Faculty of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
    J Antimicrob Chemother 45:871-5. 2000
    ..Susceptibilities to loracarbef (P < 0.001) and cefprozil were also reduced in the presence of ROB-1 while the activities of cefuroxime, cefotaxime, cefixime and imipenem were similar in both TEM- and ROB-1-positive solates...
  74. doi request reprint Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006
    Heather J Adam
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, 730 William Ave, Winnipeg, Manitoba R3E0W3, Canada
    Int J Antimicrob Agents 34:82-5. 2009
    ..Ciprofloxacin usage appears to be the biggest driver of resistance; however, total fluoroquinolone usage is also important...
  75. ncbi request reprint Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination
    Alfred Gin
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
    Expert Rev Anti Infect Ther 5:365-83. 2007
    ..Piperacillin-tazobactam has an excellent safety and tolerability profile and continues to be a reliable option for the empiric treatment of moderate-to-severe infections in hospitalized patients...
  76. pmc Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units
    Patricia J Baudry
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, R3A 1R9, Manitoba, Canada
    Antimicrob Agents Chemother 52:1846-9. 2008
    ..ESBL-producing E. coli isolates were more likely to be gentamicin resistant (P < 0.03), fluoroquinolone resistant (P < 0.0001), and multidrug resistant (P < 0.0001) than AmpC-producing E. coli isolates...
  77. ncbi request reprint Call for the international adoption of microbiological breakpoints for fluoroquinolones and Streptococcus pneumoniae
    Kristen N Schurek
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 5th Floor Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba, Canada R3E 0W3
    Int J Antimicrob Agents 28:266-9. 2006
    ..Additionally, we propose that the use of a second fluoroquinolone marker, such as ciprofloxacin, offers the best prediction for detecting an isolate possessing a first-step parC mutation...
  78. pmc Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases
    P R S Lagacé-Wiens
    Saint Boniface Hospital, Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, L4025 409 Taché Ave, Winnipeg, Manitoba, Canada R2H 2A6
    Antimicrob Agents Chemother 55:2434-7. 2011
    ..These results suggest that NXL104 may be useful in combination with β-lactams for the treatment of infections caused by ESBL- and AmpC-producing Enterobacteriaceae...
  79. pmc Pharmacodynamic modeling of clarithromycin against macrolide-resistant [PCR-positive mef(A) or erm(B)] Streptococcus pneumoniae simulating clinically achievable serum and epithelial lining fluid free-drug concentrations
    Ayman M Noreddin
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba Departments of Clinical Microbiology Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 46:4029-34. 2002
    ..pneumoniae strains, with MICs up to 8 micro g/ml. However, mef(A) isolates for which MICs are > or =16 micro g/ml along with erm(B) may result in bacteriological failures...
  80. ncbi request reprint Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003
    Kristen N Schurek
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, 5th Floor, Basic Medical Sciences Building, 730 William Avenue, Winnipeg, Manitoba, R3E 0W3, Canada
    J Antimicrob Chemother 56:769-72. 2005
    ....
  81. pmc Penicillin-binding protein 1A, 2B, and 2X alterations in Canadian isolates of penicillin-resistant Streptococcus pneumoniae
    Kimberly A Nichol
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
    Antimicrob Agents Chemother 46:3261-4. 2002
    ..5 micro g/ml had PBP 1A alterations near the STMK and SRN motifs. Sequence analysis revealed identical PBP 1A, PBP 2B, and PBP 2X substitution patterns among all isolates for which penicillin MICs were > or =1 micro g/ml...
  82. doi request reprint Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005
    James A Karlowsky
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Int J Antimicrob Agents 34:375-9. 2009
    ..Resistance development is complex and factors other than macrolide use may also be associated with observed increases in macrolide resistance in Canada from 1995 to 2005...
  83. pmc Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005
    Kimberly A Nichol
    Diagnostic Services of Manitoba Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 52:1190-4. 2008
    ..Increased genetic homogeneity among the isolates from 2003 to 2005 (cluster analysis; P < 0.001) appeared to be due to expansion of existing clonal groups and to introduction of new PFGE types...
  84. doi request reprint Antibacterial activity of guanidinylated neomycin B- and kanamycin A-derived amphiphilic lipid conjugates
    Smritilekha Bera
    Department of Chemistry, University of Manitoba, Winnipeg, Manitoba, R3T 2N2 Canada
    J Antimicrob Chemother 65:1224-7. 2010
    ....
  85. ncbi request reprint A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae
    Marek Rzeszutek
    Department of Medical Microbiology, Faculty of Medicine, Health Sciences Centre, University of Manitoba, Winnipeg, Man R3A 1R9, Canada
    Int J Antimicrob Agents 24:95-104. 2004
    ..2%) of 19 patients. After failing initial macrolide treatment, 26 (78.8%) of 33 patients received parenteral antibiotic treatment. Of 33 patients admitted to hospital, 29 (87.8%) had their outcome described as 'survived'...
  86. pmc Molecular epidemiology and prevalence of macrolide efflux genes mef(A) and mef(E) in Streptococcus pneumoniae obtained in Canada from 1997 to 2002
    Aleksandra K Wierzbowski
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    Antimicrob Agents Chemother 49:1257-61. 2005
    ..pneumoniae in Canada is mef(E) and resistance dissemination is due to both spread of the genetic element MEGA as well as clonal dissemination of penicillin- and/or macrolide-resistant strains...
  87. pmc AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity
    James A Karlowsky
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 53:3544-8. 2009
    ..Enterobacteriaceae, nonfermentative gram-negative bacilli, and Moraxella catarrhalis. These data support the continued development of AFN-1252 for the treatment of patients with resistant staphylococcal infections...
  88. ncbi request reprint Microbiological outcomes in women with diabetes and untreated asymptomatic bacteriuria
    L E Nicolle
    Section of Infectious Diseases, Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada
    World J Urol 24:61-5. 2006
    ..Asymptomatic bacteriuria is common in diabetic women. Treatment of asymptomatic bacteriuria is not beneficial, but the natural history of the microbiology of asymptomatic bacteriuria has not been well described...
  89. ncbi request reprint Antibacterial drivers of resistance
    George G Zhanel
    Department of Medical Microbiology Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    Treat Respir Med 4:13-8. 2005
    ..Antibacterial resistance is unavoidable. However, consideration of the drivers of resistance and concerted efforts to avoid these effects will help to better control the development of resistance...
  90. ncbi request reprint Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP)
    Ayman M Noreddin
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Man, Canada
    Int J Antimicrob Agents 24:479-84. 2004
    ..Levofloxacin 750 mg OD results in high probability of pharmacodynamic target attainment and improved bacteriological outcome against S. pneumoniae in patients with CAP...
  91. ncbi request reprint Genetic relatedness of multidrug-resistant Escherichia coli cultured from geographically diverse outpatient, midstream urine specimens
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada R3A 1R9
    Diagn Microbiol Infect Dis 58:283-7. 2007
    ..Antimicrobial-susceptible isolates demonstrated limited genetic relatedness, whereas 2 epidemiologic clusters containing a total of 40 isolates (57.1%) were identified among the multidrug-resistant isolates...
  92. pmc In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates
    Heather J Adam
    Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A 1R9, Canada
    Antimicrob Agents Chemother 53:4915-20. 2009
    ..015 to 128; K. oxytoca, 0.5/0.06 to 1; Proteus mirabilis, 16/0.25 to > or = 512; Pseudomonas aeruginosa, 32/< or = 0.015 to > or = 512; Acinetobacter baumannii, 1/0.12 to 16)...
  93. pmc Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada
    Kimberly A Nichol
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Health Sciences Centre, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 47:804-8. 2003
    ..These results suggest that, unlike that of penicillin resistance, the spread of S. pneumoniae ciprofloxacin resistance in Canada is currently not attributable to clonal dissemination...
  94. doi request reprint Design, synthesis, and antibacterial activities of neomycin-lipid conjugates: polycationic lipids with potent gram-positive activity
    Smritilekha Bera
    Department of Chemistry, University of Manitoba, Winnipeg, Manitoba, Canada
    J Med Chem 51:6160-4. 2008
    ..The MIC of neomycin-C16 (C20) conjugates against methicillin-resistant Staphylococcus aureus (MRSA) is comparable to clinically used antiseptics...
  95. ncbi request reprint The glycylcyclines: a comparative review with the tetracyclines
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 64:63-88. 2004
    ..e. nausea, vomiting and headache). Tigecycline appears to be a promising new antibacterial based on in vitro and pharmacokinetic/pharmacodynamic activity; however more clinical data are needed to fully evaluate its potential...
  96. doi request reprint Antibiofilm activity of sodium bicarbonate, sodium metaperiodate and SDS combination against dental unit waterline-associated bacteria and yeast
    P V Gawande
    Kane Biotech Inc, Winnipeg, MB, Canada
    J Appl Microbiol 105:986-92. 2008
    ..To determine the effect of sodium bicarbonate (SB), sodium metaperiodate (SMP) and sodium dodecyl sulfate (SDS) combination on biofilm formation and dispersal in dental unit waterline (DUWL)-associated bacteria and yeast...
  97. ncbi request reprint Antibiotic use in a Canadian Province, 1995-1998
    A G Carrie
    Faculty of Pharmacy, University of Manitoba, Winnipeg, Canada
    Ann Pharmacother 34:459-64. 2000
    ..In this study, we quantified changing patterns of antibiotic use in community practice in Manitoba, Canada, from 1995 to 1998...
  98. ncbi request reprint Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia
    George G Zhanel
    N Engl J Med 347:65-7; author reply 65-7. 2002
  99. ncbi request reprint Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims
    Heather J Smith
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    J Antimicrob Chemother 49:893-5. 2002
  100. pmc Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates
    Heather J Smith
    Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba, R3A 1R9, Canada
    Antimicrob Agents Chemother 48:3954-8. 2004
    ..However, once a ParC mutation is present, the MPC increases dramatically for all fluoroquinolones...